The Myth of "Generally Well Tolerated": Achieving Patient-Centered Assessment of Cancer Treatment Tolerability
Gita Thanarajasingam, M.D.

LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

• Review the standard approach to reporting adverse events (AEs) in cancer clinical trials, why it fails to capture tolerability and why this matters to patients with cancer.
• Introduce newer approaches to toxicity and tolerability assessment that capture AE time frame and the patient perspective.
• Discuss ongoing initiatives focused on improving our understanding of cancer treatment toxicity, tolerability and the patient experience.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.